Judit Sóvágó

Novartis (Switzerland) — Switzerland

Neuroscience · Life Sciences

20h-index1.9kcitations48works5.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroscience and Neuropharmacology Research(21), Receptor Mechanisms and Signaling(14), Neurotransmitter Receptor Influence on Behavior(13), Medical Imaging Techniques and Applications(7), Alzheimer's disease research and treatments(5)

Publications48 total

VHB937, a TREM2 Stabilizing and Activating Antibody Strongly Reduces Pathology After Peripheral Administration in a Broad Range of Animal Models for Neuroinflammation and Neurodegeneration (P4-4.004)
Neurology·2024· 5 cited
Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study
The Novartis Repository (Novartis)·2017
Active Aβ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study
Alzheimer s & Dementia Translational Research & Clinical Interventions·2016· 133 citedOpen Access
A Placebo‐Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa‐Induced Dyskinesia
Movement Disorders·2016· 34 cited
Assessment of Cognitive Outcome Measures in Teenagers with 15q13.3 Microdeletion Syndrome
Journal of Autism and Developmental Disorders·2016· 7 citedOpen Access
Characterization of brain mGluR5 binding in a pilot study of late-life major depressive disorder using positron emission tomography and [11C]ABP688
Translational Psychiatry·2015· 45 citedOpen Access
Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease
IUScholarWorks (Indiana University)·2015Open Access
Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer’s disease
Alzheimer s Research & Therapy·2015· 139 citedOpen Access
Association of Long-Term Nicotine Abstinence With Normal Metabotropic Glutamate Receptor-5 Binding
Biological Psychiatry·2015· 38 cited
P1‐360: ACTIVE AB IMMUNOTHERAPY CAD106 PHASE II DOSE‐ADJUVANT FINDING STUDY: AMYLOID PET
Alzheimer s & Dementia·2014· 1 cited
Decrease of mGluR5 receptor density goes parallel with changes in enkephalin and substance P immunoreactivity in Huntington’s disease: a preliminary investigation in the postmortem human brain
Brain Structure and Function·2014· 9 cited
Metabotropic glutamate receptor 5 binding in patients with obsessive-compulsive disorder
The International Journal of Neuropsychopharmacology·2014· 54 citedOpen Access
Marked global reduction in mGluR5 receptor binding in smokers and ex-smokers determined by [ <sup>11</sup> C]ABP688 positron emission tomography
Proceedings of the National Academy of Sciences·2012· 110 citedOpen Access
Table of Contents
Biological Psychiatry·2012Open Access
Increased Metabotropic Glutamate Receptor Subtype 5 Availability in Human Brain After One Night Without Sleep
Biological Psychiatry·2012· 93 cited
PET imaging of metabotropic glutamate receptor subtype 5 (mGluR5) in smokers
2011
Reduced Metabotropic Glutamate Receptor 5 Density in Major Depression Determined by [<sup>11</sup>C]ABP688 PET and Postmortem Study
American Journal of Psychiatry·2011· 272 citedOpen Access
Marked Global Reduction of mGluR5 Receptor Density in Smokers
2011
A metabolikus képalkotás – PET, PET/CT – onkosebészeti vonatkozásair
Magyar Sebészet (Hungarian Journal of Surgery)·2008· 1 citedOpen Access
Synthesis of C-11-labeled (S,S)-CFMME and (R)-OHDMI and their evaluation as candidate radioligands for imaging norepinephrine transporters with PET
2007
page 1 of 3Next →

Frequent Co-authors

Balázs Gulyás(26), Christer Halldin(24), Lars Farde(23), Johan Sandell(9), Simon M. Ametamey(8), Alfred Buck(8), Magnus Schou(8), Victor W. Pike(8), Baltazar Gomez‐Mancilla(7), Zsolt Cselényi(7), Valérie Treyer(6), Anass Johayem(6), Gregor Hasler(6), Béla Kiss(6), Ádám Vas(6), Angelika Caputo(5), Ana Graf(5), Funda Akkus(5), Cyrill Burger(4), Martin R. Farlow(4)